March 2018, Supplement - Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on current incidence rates, 12.4% of women born in the United States today will develop breast cancer at some time during their life.1 At the time of diagnosis, breast cancer is generally considered local, but eventually approximately 20% of patients will experience either locoregional or distant disease recurrence.2
Over the past 3 decades, biologic medicines have played an increasingly significant role in healthcare around the world and have changed standards of care for patients. Now, biopharmaceutical research and commitment to value-based care have prompted the pursuit of biosimilar drugs, or biologic drugs that are “highly similar” to approved biologics.
Eli O. Meltzer, MD, Don A. Bukstein, MD, Paul M. Hamrah, MS, PharmD, Nikkia Scott, PharmD, John A. Welz, MPH
Sarilumab (Kevzara) is a novel interleukin (IL)-6 receptor inhibitor that was approved by the US Food and Drug Administration (FDA) on May 22, 2017, for the treatment of adults with moderately or severely active RA who have had an inadequate response or intolerance to 1 or more DMARDs.
Approximately 75% of breast cancers rely on ER signaling to grow and survive.2 Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.3 However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).3
An increased understanding of the molecular pathogenesis of RA has led to significant advances in biologic therapies in the past 15 years and has dramatically changed the treatment paradigm for RA.3 Currently, 4 classes of biologic DMARDs are available, including (1) the tumor necrosis factor (TNF)-α inhibitors adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab; (2) abatacept, which blocks T-cell costimulation via anti-CD80/86 inhibition; (3) the anti-CD20 agent that causes B-cell depletion, rituximab; and (4) the interleukin (IL)-6 receptor (IL-6R) blocker, tocilizumab.
￼A Multidisciplinary Approach to the Treatment of Prostate Cancer: Providing Therapies That Improve Overall Survival and Quality of Life
Page 1 of 5
Results 1 - 10 of 46
Results 1 - 10 of 46